Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) was down 11.7% during trading on Monday . The stock traded as low as $0.47 and last traded at $0.48. Approximately 1,319,186 shares changed hands during mid-day trading, an increase of 72% from the average daily volume of 766,801 shares. The stock had previously closed at $0.54.
Several equities research analysts recently commented on ATNM shares. Maxim Group set a $3.00 price target on shares of Actinium Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, February 5th. Oppenheimer set a $5.00 target price on shares of Actinium Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, February 26th. Finally, Zacks Investment Research raised shares of Actinium Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 target price on the stock in a research note on Monday, April 1st. Five equities research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and a consensus target price of $3.50.
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last announced its earnings results on Tuesday, March 19th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.06).
Actinium Pharmaceuticals Company Profile (NYSEAMERICAN:ATNM)
Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older.
See Also: Closed-End Mutual Funds
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.